Fortitude Family Office’s Solid Biosciences SLDB Stock Holding History

Fortitude Family Office’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$769	Hold	77	–	–	﹤0.01%	1845
2026 Q1	$554	Buy	+77	New	+$495	﹤0.01%	1687

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fortitude Family Office's SLDB Position: Q2 2026 in Review

Fortitude Family Office held its Solid Biosciences (SLDB) position steady in Q2 2026 at 77 shares worth $769. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Fortitude Family Office first reported a position in SLDB in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Fortitude Family Office held 77 shares of Solid Biosciences worth $769 as of Q2 2026.
Fortitude Family Office left its Solid Biosciences share count unchanged in Q2 2026.
Solid Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1845 holding.
Fortitude Family Office first reported a position in Solid Biosciences in Q1 2026 and has held it in 2 quarters since.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.